Skip to main navigation Skip to search Skip to main content

An in silico reverse vaccinology study of Brachyspira pilosicoli, the causative organism of intestinal spirochaetosis, to identify putative vaccine candidates

  • Myron Christodoulides*
  • , Daysiane de Oliveira
  • , David W. Cleary
  • , Maria Victoria Humbert
  • , Ricardo A. Machado-de-Ávila
  • , Roberto M. La Ragione
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

104 Downloads (Pure)

Abstract

Brachyspira pilosicoli is a zoonotic bacterium that can cause intestinal spirochaetosis (IS) in avian species (AIS), pigs (PIS) and humans (HIS). In the absence of vaccines to prevent infections, we used genome-based reverse vaccinology (RV) to identify putative B. pilosicoli vaccine candidates. Genome sequence of B. pilosicoli strain B2904, an AIS isolate, was analysed with PSORTb3, CELLO, SOSUIGramN, LipoP, SignalP-5.0, TMHMM, BLAST 2.12.0 +, PDB database, SEED Viewer, eggNOG-mapper, UniProt, VaxiJen and Vaxign2, and Tblastn to generate a RV list of putative vaccine candidates. We also generated a linear B-cell chimera antigen using Blast-p, Emini Surface Accessibility Prediction, ABCpred, Expasy ProtParam and PepCalc programs. RV defined a list of 162 proteins containing 48 Outer Membrane (OM), 27 OM/Extracellular, 27 Extracellular, 4 Periplasm, 2 Surface, 2 Cytoplasm and 52 Unknown proteins. The list was characterised by an abundance of SPII lipoproteins. We found that genes encoding amino acid sequences of 146/162 (90%) proteins were present in 19 other B. pilosicoli genomes. A linear B-cell chimera antigen was generated from the amino acid sequences of 18 OM and Extracellular proteins. Our contemporary RV study represents a starting point for a comprehensive vaccine development strategy for preventing intestinal spirochaetosis.

Original languageEnglish
Pages (from-to)128-148
Number of pages21
JournalProcess Biochemistry
Volume122
Early online date18 Aug 2022
DOIs
Publication statusPublished - Nov 2022

Bibliographical note

Funding Information:
MC and RML were in receipt of a Houghton Trust UK (Avian Pathology) research award (unnumbered) for research into diseases of avian species and domestic poultry. We are grateful to Dr. Maria Scarselli, Glaxo Smith Kline Vaccines Srl, Siena, Italy, for instruction in in silico reverse vaccinology.

Publisher Copyright:
© 2022 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • B-cell chimera
  • Brachyspira pilosicoli
  • in silico
  • Reverse vaccinology
  • Vaccine

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Applied Microbiology and Biotechnology

Fingerprint

Dive into the research topics of 'An in silico reverse vaccinology study of Brachyspira pilosicoli, the causative organism of intestinal spirochaetosis, to identify putative vaccine candidates'. Together they form a unique fingerprint.

Cite this